MONTREAL Quebec doctors will receive a recommendation early this week from a provincial drug evaluation committee on whether they should prescribe the medication colchicine to treat non-hospitalized COVID-19 patients. The update comes after a tumultuous week that started with a prominent Montreal Heart Institute (MHI) researcher making bold claims in a press release about the effectiveness of the medication and ended with pushback after many scientists were eventually able to scrutinize the study’s data themselves. “We anticipate making our interim position public at the beginning of the week, Tuesday being very likely,” National Institute for Excellence in Health and Social Services (INESSS)spokesperson Olivia Jacques told CTV in an email.
Covid-19-Therapie: Positive klinische Daten zu Colchicin
pharmazeutische-zeitung.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmazeutische-zeitung.de Daily Mail and Mail on Sunday newspapers.
El azafrán silvestre, habitual en Mallorca, el último milagro para tratar a pacientes con la COVID-19
ultimahora.es - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ultimahora.es Daily Mail and Mail on Sunday newspapers.
El ensayo de la colchicina sugiere que los más beneficiados podrían ser algunos grupos de riesgo
elpais.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from elpais.com Daily Mail and Mail on Sunday newspapers.
MONTREAL Many in the international science community reacted with disappointment and not a little frustration on Wednesday, after finally seeing statistical data from a study on the effectiveness of medication colchicine. “We can confirm that the primary outcome was not statistically significant,” said Dr. Emily McDonald a scientist at the MUHC’s Research Institute. The anti-inflammatory drug, now used to treat gout was touted by the Montreal Heart Institute just days ago in a press release, as an effective oral medication for non-hospitalized COVID-19 patients. In a Friday press release, the MHI researchers claimed the drug reduced the risk of death or hospitalization for COVID-19 by 21 per cent.